Attending Rounds a Woman with Recurrent Calcium Phosphate

Total Page:16

File Type:pdf, Size:1020Kb

Attending Rounds a Woman with Recurrent Calcium Phosphate Attending Rounds A Woman with Recurrent Calcium Phosphate Kidney Stones David S. Goldfarb Summary Kidney stones composed predominantly (50% or more) of calcium phosphate constitute up to 10% of all stones and 15%–20% of calcium stones, 80% of which are composed of calcium oxalate. Calcium phosphate is a minor component of up to 30% of calcium oxalate stones as well. The cause of calcium phosphate stones is often obscure Nephrology Section, New York Harbor but most often related to a high urine pH. Some patients with calcium phosphate stones may have incomplete renal Department of tubular acidosis. Others have distal renal tubular acidosis characterized by hyperchloremic acidosis, hypocitraturia, Veterans Affairs and high urine pH. The use of carbonic anhydrase inhibitors such as acetazolamide, topiramate, and Healthcare System, zonisamide leads to a similar picture. Treatment options to specifically prevent calcium phosphate stone recur- New York, New York; Endourology Section, rence have not been tested in clinical trials. Increases in urine volume and restriction of sodium intake to limit Lenox Hill Hospital, calcium excretion are important. Citrate supplementation is probably effective, although the concomitant in- New York, New York; crease in urine pH may increase calcium phosphate supersaturation and partially offset the inhibition of crys- and Division of tallization resulting from the increased urine citrate excretion and the alkali-associated reduction in urine calcium Nephrology, New excretion. Thiazides lower urine calcium excretion and may help ensure the safety of citrate supplementation. York University Langone Medical Clin J Am Soc Nephrol 7: 1172–1178, 2012. doi: 10.2215/CJN.00560112 Center, New York, New York Introduction calcium was 9.4 mg/dl, potassium was 4.7 meq/L, Correspondence: Dr. A 22-year-old woman who had her first kidney stone HCO was 24 meq/L, 25-OH-vitamin D was 32 ng/ml, David S. Goldfarb, 3 423 East 23rd Street/ at age 15 years was seen in the Kidney Stone Prevention and intact parathyroid hormone (PTH) was 23 pg/ml. 111G, New York, NY Clinic because of recurrent calcium stones. In total, She performed 24-hour urine collections (Table 1). All 10010. Email: david. she has had five episodes of acute renal colic in 7 years. collections had similar creatinine excretion, indicating [email protected] Each episode was associated with more than one stone that the collections were comparable and consistent. causing at least temporary ureteral obstruction that At baseline, the results were notable for a very low required urologic intervention. She has had one unsuc- volume less than 1 L and normal calcium, oxalate, cessful shock-wave lithotripsy and five ureteroscopies. phosphate, and uric acid excretion, with relatively Stone composition has been variable: her first stone low sodium excretion and very low citrate excretion. was 80% calcium oxalate and 20% calcium phosphate; As expected in a calcium phosphate stone former, her 4 years later, 80% calcium phosphate and 20% calcium urine pH was relatively high. The calculated supersat- oxalate; 1 year later, a lab reported that one of her uration values indicated moderate risk of calcium oxa- stones was composed of 50% brushite, 20% hydroxy- late and calcium phosphate crystallization. apatite and 30% calcium oxalate; most recently a stone was reported to be 100% carbonate apatite. She had no Therapy history of urinary tract infections. She was prescribed potassium citrate 15 meq two She is physically active and does aerobic exercises. times per day and told to increase her fluid intake to at She has not been on any weight loss diets, and eats least 3 L (about 100 oz) per day. She was counseled to “everything”, including milk with cereal, and some continue to limit her sodium and oxalate intake and yogurt. She is not taking any medications but 1 year have two to three servings of dairy products with ago, had taken potassium citrate 15 meq two times meals per day, which she had been avoiding. A repeat per day for 5 months and then stopped it when she urine collection several months later (Table 1, Treat- concluded that it had not been effective. She has no ment 1) showed increased potassium, citrate, sodium, history of hypertension or diabetes. Both her father and calcium excretion, with a significant increase in and paternal grandfather had stones of uncertain com- urine volume and pH. Despite the increased calcium position. On physical exam, she had a seated blood excretion, the net effect was reduction in supersatura- pressure of 114/78 mmHg. She is 165 cm tall and tion of both calcium oxalate and calcium phosphate. weighs 74.8 kg, with body mass index of 27.5 kg/m2. Her increased sodium excretion was associated with an increase in calcium excretion and was probably Laboratory Evaluation more representative of her typical sodium intake. Al- Review of laboratory evaluations showed that serum though the resulting calciuria did not constitute hyper- creatinine was 0.8 mg/dl, uric acid was 5.2 mg/dl, calciuria and because she was highly motivated to 1172 Copyright © 2012 by the American Society of Nephrology www.cjasn.org Vol 7 July, 2012 Clin J Am Soc Nephrol 7: 1172–1178, July, 2012 Table 1. 24-Hour urine chemistries Supersaturation Supersaturation Uric Volume Sodium Potassium Calcium Oxalate Citrate Phosphorus Creatinine Calcium pH Calcium Acid (L) (meq) (meq) (mg) (mg) (mg) (mg) (mg) Oxalate Phosphate (mg) Normal 0.5–4.0 50–150 20–100 M,250; 20–40 8–10 M.450; 5.8–6.2 0.5–2.0 800–1200 M,800; M=18–24 values F,200 F.550 F,750 mg/kg; F=15–20 mg/kg Baseline 0.86 55 60 92 31 9.5 103 6.45 1.9 586 551 1379 Treatment 1 2.49 152 81 175 24 3.1 218 7.49 1.4 525 396 1412 Treatment 2 1.97 209 53 93 37 3.2 196 7.24 1.2 859 600 1352 Normal values apply to the general population but do not represent the optimal values to lower stone risk. Baseline represents the mean of two collections performed before the patient’s first clinic visit. M, male; F, female. for distal renal tubularDefective acidosis Renal (dRTA). Tubular Acidification A low serum phate to avoid inaccuracy. uncertainty, some labsliability simply report of basic thiscrystalline calcium determination phases, phos- (6). leading In tocium some recognition phosphate question stones of about reportedshow this different the that re- results different forwhich these laboratories is analyzing seencalcium the in phosphate same the stones cal- currentbonate not patient apatite (5). cansociated be Recent with present data urease-producing in organisms. patients However, with car- idiopathic growths on Randall the vast majoritystones of has calcium been oxalate highlightedimportance stones of by form calcium recent as phosphate workof over- as showing an up initiator that of to calcium calcium 30% oxalate. Calcium of phosphate calcium15% is a oxalate minor stones component of as calcium phosphate well constitute up (1). to 10% The of allOverview stones and of Calcium PhosphateCase Stones Discussion regarding restriction ofbaseline dietary value sodium. ofa 4.7 serum meq/L). potassium Sheand level was serum of again chemistry 3.9 counseled phosphate values meq/L were changed (lower unchanged, signi thanneither including her supersaturation ofsodium calcium excretion; oxalate urine norto volume calcium the was slightly indapamide,showed lower, despite a and reduction a in further urine1 calcium increase month excretion in attributable later urine one (Table time 1, each Treatmentavoid day 2). additional and That stones, repeated collection I the prescribed urine indapamide collection 2.5 mg the ammonium ruled out, particularlycomponent if it of exists stones combinedbrushite should is with not have struvite, known. urinarythe Patients with tract form carbonate infection of apatitehydroxyapatite. as hydroxyapatite a Why some and calcium othersis phosphate a take stones less take the stablehydrogen form crystal phosphate) structure of is that lesssame common, often crystal probably transforms form because into thatpresented it composes here. bones; The brushitein most (calcium kidney common stones, is and hydroxyapatite, these the forms occurredspeculative. in the patient defective urinary acidi otripsy (3,4). Lithotripsy hasbelow) been or hypothesized adverse effects to ofbeen lead extracorporeal attributed to shockwave to lith- treatmentin with prevalence. citrate If supplements true,data (see suggest the that reasons calcium are phosphatecrystals stones uncertain nucleate have and increased and have urothelium grow and becomes into exposed kidney toand urine; stones it calcium (2). oxalate growsphous Some until apatite that it forms ruptures in the through interstitium the of the papillary papillae, Calcium phosphate stone formers should be evaluated Kidney stones composed predominantly (50% or more) There are several forms of calcium phosphate that appear – 20% of calcium stones, 80% of which are composed of – Recurrent Calcium Phosphate Stones, Goldfarb 1173 magnesium ’ fi s plaque. Randall cation, but this effect is highly fi – cantly. Her blood pressure calcium phosphate crystal as- associated with infection, ’ splaqueisanamor- 1174 Clinical Journal of the American Society of Nephrology bicarbonate concentration, hyperchloremic metabolic aci- fasting and 24-hour urine pH compared with calcium dosis, and persistently alkaline urine pH of at least 5.5 stone formers who did not have incomplete dRTA. In an- is diagnostic. Hypokalemia is frequently present as well. other study, an inability to lower the urine pH below 5.25 Metabolic acidosis and hypokalemia both contribute to was present in calcium phosphate stone formers but not hypocitraturia. Hypercalciuria is frequent, and in the pres- calcium oxalate stone formers (11). Because appropriate ence of a consistently elevated urine pH, these urinary therapy addressing the specific urine chemistry abnormal- characteristics lead to calcium phosphate precipitation. ities will be the same whether incomplete RTA is diag- Nephrocalcinosis (calcification of the renal parenchyma) is nosed or not, ammoniuim chloride loading is rarely done often present and may lead to reduced GFR.
Recommended publications
  • Educate Your Patients About Kidney Stones a REFERENCE GUIDE for HEALTHCARE PROFESSIONALS
    Educate Your Patients about Kidney Stones A REFERENCE GUIDE FOR HEALTHCARE PROFESSIONALS Kidney stones Kidney stones can be a serious problem. A kidney stone is a hard object that is made from chemicals in the urine. There are five types of kidney stones: Calcium oxalate: Most common, created when calcium combines with oxalate in the urine. Calcium phosphate: Can be associated with hyperparathyroidism and renal tubular acidosis. Uric acid: Can be associated with a diet high in animal protein. Struvite: Less common, caused by infections in the upper urinary tract. Cystine: Rare and tend to run in families with a history of cystinuria. People who had a kidney stone are at higher risk of having another stone. Kidney stones may also increase the risk of kidney disease. Symptoms A stone that is small enough can pass through the ureter with no symptoms. However, if the stone is large enough, it may stay in the kidney or travel down the urinary tract into the ureter. Stones that don’t move may cause significant pain, urinary outflow obstruction, or other health problems. Possible symptoms include severe pain on either side of the lower back, more vague pain or stomach ache that doesn’t go away, blood in the urine, nausea or vomiting, fever and chills, or urine that smells bad or looks cloudy. Speak with a healthcare professional if you feel any of these symptoms. Risk factors Risk factors can include a family or personal history of kidney stones, diets high in protein, salt, or sugar, obesity, or digestive diseases or surgeries.
    [Show full text]
  • Remineralisation of Enamel Subsurface Lesions with Casein Phosphopeptide - Amorphous Calcium Phosphate in Patients with Fixed Orthodontic Appliances
    Y T E I C O S L BALKAN JOURNAL OF STOMATOLOGY A ISSN 1107 - 1141 IC G LO TO STOMA Remineralisation of Enamel Subsurface Lesions with Casein Phosphopeptide - Amorphous Calcium Phosphate in Patients with Fixed Orthodontic Appliances SUMMARY Darko Pop Acev1, Julijana Gjorgova2 One of the most common problems in everyday dental practice is the 1PZU Pop Acevi, Skopje, FYROM occurrence of dental caries. The easiest way to deal with this problem is its 2Department of Orthodontics prevention. A lot of research has been done to find a material that would “Ss. Cyril and Methodius” University, Skopje help to prevent the occurrence of dental caries, which means to stop tooth FYROM demineralization (loss of minerals from the tooth structure) and replace it with the process of remineralisation (reincorporating minerals in dental tissue). In this review article we will present the remineralisation potential of casein phosphopeptide - amorphous calcium phosphate (CPP-ACP) in clinical studies. We considered all articles that were available through the browser of Pubmed Central. After analyzing the results obtained from these studies, we concluded that casein phosphopeptide - amorphous calcium phosphate has significant remineralisation effect when used in patients with fixed orthodontic appliances. Keywords: Dental Remineralisation; Casein Phosphopeptide; Amorphous Calcium LITERATURE REVIEW (LR) Phosphate Balk J Stom, 2013; 17:81-91 Introduction of the enamel porous and sensitive to internal and external factors9. Apart of this, maintaining oral hygiene Dental caries is defined as localized destruction of is difficult in patients with fixed orthodontic appliances; tooth hard tissue with acids, produced during fermentation this is the reason for accumulating food debris on the of carbohydrates, by bacteria in dental plaque1,2.
    [Show full text]
  • Spray-Dried Monocalcium Phosphate Monohydrate for Soluble Phosphate Fertilizer Khouloud Nasri, Hafed El Feki, Patrick Sharrock, Marina Fiallo, Ange Nzihou
    Spray-Dried Monocalcium Phosphate Monohydrate for Soluble Phosphate Fertilizer Khouloud Nasri, Hafed El Feki, Patrick Sharrock, Marina Fiallo, Ange Nzihou To cite this version: Khouloud Nasri, Hafed El Feki, Patrick Sharrock, Marina Fiallo, Ange Nzihou. Spray-Dried Monocal- cium Phosphate Monohydrate for Soluble Phosphate Fertilizer. Industrial and engineering chemistry research, American Chemical Society, 2015, 54 (33), p. 8043-8047. 10.1021/acs.iecr.5b02100. hal- 01609207 HAL Id: hal-01609207 https://hal.archives-ouvertes.fr/hal-01609207 Submitted on 15 Jan 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Spray-Dried Monocalcium Phosphate Monohydrate for Soluble Phosphate Fertilizer Khouloud Nasri and Hafed El Feki Laboratory of Materials and Environmental Sciences, Faculty of Sciences of Sfax, Soukra Road km 4B. P. no 802−3038, Sfax, Tunisia Patrick Sharrock* and Marina Fiallo Université de Toulouse, SIMAD, IUT Paul Sabatier, Avenue Georges Pompidou, 81104 Castres, France Ange Nzihou Centre RAPSODEE, Université de Toulouse, Mines Albi, CNRS, Albi, France ABSTRACT: Monocalcium phosphate monohydrate (MCPM) was obtained by water extraction of triple superphosphate. The solubility of MCPM is 783.1 g/L, and is entirely soluble. Saturated MCPM solution dissociates into free phosphoric acid and monetite (CaHPO4), but evaporation to dryness by spray drying forms MCPM during crystallization.
    [Show full text]
  • Phosphate & Rock
    IOSR Journal of Environmental Science, Toxicology and Food Technology (IOSR-JESTFT) e-ISSN: 2319-2402,p- ISSN: 2319-2399.Volume 8, Issue 11 Ver. III (Nov. 2014), PP 22-39 www.iosrjournals.org Comparative Study Of Rock Phosphate And Calcium Phosphate On The Growth &Biochemistry Of Brassica Juncea And It’s Impact On Soil Heath Sandhya Buddh Department Of Biotechnology Boston College For Professional Studies, Gwalior Abstract: A study was conducted to compare the effect of rock phosphate & calcium phosphate on the growth and the biochemistry of the plant Brassica juncea and its impact on soil health. The rock phosphate is highly favorable than tri-calcium phosphate for the mustard growth. Physiochemical effect of the plant was evaluated through the analysis of amino acid, pigment, shoot & root biomass content of the plant. The following parameters of soil (treated with Tri calcium phosphate & Rock phosphate) such as pH, EC, moisture, ash were analyzed. The pH of the soil mixed with tri-calcium phosphate and rock phosphate was decreased slightly from original & EC was increased .Impact of rock phosphate & calcium phosphate on the soil health can be observed by calculating TOC and nitrogen estimation at regular interval of days. Nitrogen concentration at 5th day is gradually decreases except control, R2 and R4 and after in 10th day and 20th day it becomes increased. The highest TOC value was observed on 10th day i.e. (C1)9.64 in calcium phosphate and R1 (10.17) on 1st day in rock phosphate. I. Introduction Phosphorus, one of the 17 chemical elements required for plant growth and reproduction, is often referred to as the ―energizer‖ since it helps store and transfer energy during photosynthesis.
    [Show full text]
  • Sonochemical Synthesis of Cellulose/Hydroxyapatite
    www.nature.com/scientificreports OPEN Sonochemical synthesis of cellulose/hydroxyapatite nanocomposites and their Received: 10 January 2018 Accepted: 20 April 2018 application in protein adsorption Published: xx xx xxxx Lian-Hua Fu1,2,3, Chao Qi2, Yan-Jun Liu1, Wen-Tao Cao1 & Ming-Guo Ma 1 Hydroxyapatite (HA) is the main mineral constituent in the hard tissue of vertebrate, which is recognized as an important biomedical material owing to its excellent bioactivity and biocompatibility. Herein, we report a facile and green sonochemical route for the rapid synthesis of cellulose/ HA nanocomposites in NaOH/urea aqueous solution. The in vitro behavior of the cellulose/HA nanocomposites was studied to evaluate the biological response of the nanocomposites following immersion in simulated body fuid for various periods (maximum of 28 days). The HA crystals formed on the surface of the nanocomposites were carbonate-containing apatite, which is similar to the naturally occurring calcium phosphate materials. The HA nanosheets (assembly of nanorods) were mineralized on the surface of the nanocomposites, and maximum mass of the nanocomposites was reached 1.82 times of initial mass after 28 days of soaking. Moreover, the as-prepared cellulose/HA nanocomposites have good cytocompatibility, and show a relatively high protein adsorption ability using hemoglobin as a model protein. These results indicate that the as-prepared cellulose/HA nanocomposites are promising for applications in various biomedical felds such as tissue engineering and protein/drug delivery. Hydroxyapatite (HA) is the main mineral component in the hard tissue of vertebrate bones and teeth as well as the most stable calcium phosphate phase under physiological conditions1,2.
    [Show full text]
  • Enhanced Remineralisation of Tooth Enamel Using Casein Phosphopeptide-Amorphous Calcium Phosphate Complex: a Review
    Review Article Int J Clin Prev Dent 2018;14(1):1-10ㆍhttps://doi.org/10.15236/ijcpd.2018.14.1.1 ISSN (Print) 1738-8546ㆍISSN (Online) 2287-6197 Enhanced Remineralisation of Tooth Enamel Using Casein Phosphopeptide-Amorphous Calcium Phosphate Complex: A Review Nidhi Chhabra, Anuj Chhabra Department of Dental Surgery, North DMC Medical College and Hindu Rao Hospital, Delhi, India The protective effects of milk and milk products against dental caries, due to micellar casein or caseinopeptide derivatives, have been demonstrated in various animal and human in situ studies. Among all the remineralising agents, casein phospho- peptide-amorphous calcium phosphate (CPP-ACP) technology has shown the most promising scientific evidence to support its use in prevention and reversal of carious lesions. CPP-ACP complex acts as a calcium phosphate reservoir and buffer the activities of free calcium and phosphate ions in the plaque. Calcium phosphate stabilized by CPP produces a metastable sol- ution supersaturated with respect to the amorphous and crystalline calcium phosphate phases, thereby depressing enamel demineralisation and enhancing mineralisation. CPP-ACP provides new avenue for the remineralisation of noncavitated ca- ries lesions. The objective of this article was to review the clinical trials of CPP-ACP complex and highlight its evidence based applications in dentistry. Keywords: remineralisation, casein derivatives, casein phospho peptide-amorphous calcium phosphate Introduction from an imbalance in the physiological process of remineralisa- tion/demineralisation of the tooth structure and results in the Recent scientific advances in restorative materials, techni- formation of a subsurface lesion [1]. At an early stage, the caries ques and better understanding of the etiology, pathogenicity and lesion is reversible via remineralisation process involving the prevention of caries, have led to more efficient management of diffusion of calcium and phosphate ions into the subsurface le- oral health.
    [Show full text]
  • Calcium and Phosphate Balance in CKD
    Calcium and phosphate balance in CKD Sharon M. Moe, MD Indiana University School of Medicine Roudebush Veterans Affairs Medical Center Indiana University Health Partners Indianapolis, IN, USA Disclosures • Dr. Moe has current grant support from the NIH, the Veterans Administration, Novartis • The balance study was funded by Genzyme/ Sanofi to Dr. Munro Peacock; Dr. Moe was a co-investigator. • Dr. Moe has served as a scientific advisor/ consultant/received honoraria for Amgen and Sanofi. Current KDIGO Guidelines • 4.1.4. In patients with CKD stages 3–5 (2D) and 5D (2B), we suggest using phosphate-binding agents in the treatment of hyperphosphatemia. It is reasonable that the choice of phosphate binder takes into account CKD stage, presence of other components of CKD–MBD, concomitant therapies, and side-effect profile (not graded). • 4.1.5. In patients with CKD stages 3–5D and hyperphosphatemia, we recommend restricting the dose of calcium-based phosphate binders and/or the dose of calcitriol or vitamin D analog in the presence of persistent or recurrent hypercalcemia (1B). • In patients with CKD stages 3–5D and hyperphosphatemia, we suggest restricting the dose of calcium-based phosphate binders in the presence of arterial calcification (2C) and/or adynamic bone disease (2C) and/or if serum PTH levels are persistently low (2C). K/DOQI Guidelines In CKD Patients (Stages 3 and 4): • 5.2 Calcium-based phosphate binders are effective in lowering serum phosphorus levels (EVIDENCE) and may be used as the initial binder therapy. (OPINION) In CKD Patients With Kidney Failure (Stage 5): • 5.3 Both calcium-based phosphate binders and other noncalcium-, nonaluminum-, nonmagnesium-containing phosphate-binding agents (such as sevelamer HCl) are effective in lowering serum phosphorus levels (EVIDENCE) and either may be used as the primary therapy.
    [Show full text]
  • Nutrient Value of the Phosphorus In
    NUTRIENT VALUE OF THE PHOSPHORUS IN DEFLUORI- NATED PHOSPHATE, CALCIUM METAPHOSPHATE, AND OTHER PHOSPHATIC MATERIALS AS DETERMINED BY GROWTH OF PLANTS IN POT EXPERIMENTS ' By K. D. JACOB and WILLIAM H. ROSS, senior chemists. Fertilizer Research Divi- sion, Bureau of Agricultural Chemistry and Engineering, United States Depart- ment of Agriculture ^ ^ INTRODUCTION In recent years much work has been done on the development of methods for the production of new phosphatic materials suitable for use as fertilizer. Some of these materials, particularly defluorinated phosphate, calcium metaphosphate, and potassium metaphosphate, offer considerable promise as sources of phosphorus for plant growth, either because of their high content of plant food and the consequent- economy in transportation and handling costs or because of the possi- bility of effecting a considerable reduction in processing costs. In either case the primary object/)f the work is to supply the farmer with cheaper phosphate and at the same time to maintain at a high level the nutrient value of the phosphorus contained therein. Defluorinated phosphate (prepared by heating phosphate rock at high temperatures in the presence of water vapor and silica) has been produced experimentally in two forms—calcined phosphate and fused phosphate rock—which differ in certain physical characteristics, but which appear to be identical in chemical structure (28) ^ Calcined phosphate, obtained in the form of a sintered or semifused, more or less porous clinker, is prepared by defluorinating phosphate rock at temperatures below the melting point of the charge, usually at 1,400° C. (85j 46, 58, 59, 60). Fused phosphate rock, obtained in the form of a hard glassy material, is prepared by defluorinating phosphate rock at temperatures above the melting point of the charge, usually at about 1,550° C.
    [Show full text]
  • Calcium and Phosphate Compatibility: Revisited Again
    COMMENTARY Calcium and phosphates COMMENTARY • The influence of other drugs and Calcium and phosphate compatibility: nutrients.4-8,10-18 Revisited again The application of knowledge about calcium and phosphate com- DAVI D W. NE W TO N A nd DAVI D F. DRISCOLL patibility in i.v. therapy has been fa- 3-6 Am J Health-Syst Pharm. 2008; 65:73-80 cilitated by four hallmark articles, several editions of the Handbook on he subject of the compatibility • The clinically relevant dissocia- Injectable Drugs17 since 1983, and between calcium and phosphates tion equilibria for which the pKa2 of Trissel’s Calcium and Phosphate Com- was revisited in an April 1994 phosphoric acid is 7.2 (i.e., the pH patibility in Parenteral Nutrition.18 T 1,2 FDA safety alert, 6–16 years after at which the concentrations or, ther- Despite the availability of these the four seminal research articles modynamically, the ionic activities of literature sources, calcium and phos- 3 4 5 2– – appeared in 1978, 1980, 1982, HPO4 and H2PO4 are equal) (Table phate compatibility continues to be a and 1988.6 In the 1980s there were 1): clinical enigma. two case reports of nonfatal adverse Physicochemical factors. Calcium – – 2– events involving calcium phosphate OH + H2PO4 ↔ HPO4 + H2O; shifts and phosphate solubility chemistry. precipitation in total parenteral nu- to right when pH increases (1) The aqueous chemistry and solubil- 7,8 – 2– + trient (TPN) admixtures. A review H2O + H2PO4 ↔ HPO4 + H3O ; ity of the two phosphate anions and of the main determinants of paren- shifts to left when pH decreases (2) their calcium salts that are important teral drug and admixture compat- to the safety of i.v.
    [Show full text]
  • Calcium Phosphate Kidney Stone: Problems and Perspectives Daniel Callaghan and Bidhan C
    ogy: iol Cu ys r h re P n t & R y e s Anatomy & Physiology: Current m e Callaghan and Bandyopadhyay, Anat Physiol 2012, 2:4 o a t r a c DOI: 10.4172/2161-0940.1000e118 n h A Research ISSN: 2161-0940 Editorial Open Access Calcium Phosphate Kidney Stone: Problems and Perspectives Daniel Callaghan and Bidhan C. Bandyopadhyay* Calcium Signaling Laboratory, DVA Medical Center, Washington DC, USA Acute renal colic due to kidney stones is probably the most obstructions [8]; v) medications such as acetazolamide, calcium excruciatingly painful event a person can endure. This painful event, antacids, glucocorticoids, loop diuretics, theophylline, and vitamin D which starts without warning, is often described as being worse than [9,11]. In living systems, all of these factors are intertwined with each childbirth, broken bones, gunshot wounds, burns, or surgery. Kidney other, along with the overwhelming complexity of cellular behaviors, stone disease, or nephrolithiasis, is a common disease that is estimated regulatory pathways, and differences in renal pathology in individuals. to produce medical costs of $2.1 billion per year in the United States. This poses a great challenge in the ability to understand and predict the Renal colic affects approximately 1.2 million people each year and biomineralization process. To date, the mechanism by which crystals accounts for approximately 1% of all hospital admissions. The incidence grow into stones is still poorly understood. For instance, some suggest of kidney stone disease has been increasing in the United States over that the attachment of preformed microcrystals to the surface of renal recent years and it is now estimated that approximately 5% of American tubular cells leads to the further deposition of crystals and eventual women and 12% of American men will be affected at some point in formation of full-sized stones.
    [Show full text]
  • A Brief Review on Hydroxyapatite Production and Use in Biomedicine
    282 Cerâmica 65 (2019) 282-302 http://dx.doi.org/10.1590/0366-69132019653742706 A brief review on hydroxyapatite production and use in biomedicine (Uma breve revisão sobre a obtenção de hidroxiapatita e aplicação na biomedicina) D. S. Gomes1,2*, A. M. C. Santos2, G. A. Neves1,2, R. R. Menezes1,2 1Federal University of Campina Grande, Graduating Program in Materials Science and Engineering, Campina Grande, PB, Brazil 2Federal University of Campina Grande, Department of Materials Engineering, Av. Aprígio Veloso 882, 58109-970, Campina Grande, PB, Brazil Abstract Hydroxyapatite (HAp) is a bioceramic widely studied due to its chemical similarity with the mineral component of bones. Besides, it is biocompatible, bioactive and thermodynamically stable in the body fluid what poses it as an attractive material for a wide range of applications in the biomedical field. Several efforts have been focused on the synthesis of particles of this material aiming to the precise control of size and morphology, porosity and surface area. HAp is widely used as an implant for bone tissue regeneration, as a coating for metallic implants and in a drug-controlled release. In this sense, the objective of this review is to gather information related to HAp, providing readers with information about synthesis methods, material characteristics and their applications. Keywords: hydroxyapatite, synthesis, biomedical applications. Resumo A hidroxiapatita (HAp) é uma biocerâmica amplamente estudada devido à sua similaridade química com o componente mineral dos ossos. Além disso, é biocompatível, bioativa e termodinamicamente estável no fluido corporal, o que a coloca como um material atraente para uma ampla gama de aplicações no campo biomédico.
    [Show full text]
  • Non-Fluoridated Remineralising Agents - a Review of Literature
    Jemds.com Review Article Non-Fluoridated Remineralising Agents - A Review of Literature Akriti Batra1, Vabitha Shetty2, 1, 2, Department of Paediatric & Preventive Dentistry, A.B. Shetty Memorial Institute of Dental Sciences (NITTE Deemed to Be University), Derlakatte, Mangalore, Karnataka, India. ABSTRACT Dental caries is not merely a continuous and one-way process of demineralisation of Corresponding Author: the mineral phase, but repeated episodes of demineralisations and remineralisation. Dr. Vabitha Shetty, The remineralisation process is a natural repair mechanism to restore the minerals Capitol Apartments, Flat No. 702, again, in ionic forms, to the hydroxyapatite (HAP) crystal lattice. It occurs under near- Mangalore, Karnataka, India. E-mail: [email protected] neutral physiological pH conditions whereby calcium and phosphate mineral ions are redeposited within the caries lesion from saliva and plaque fluid resulting in the DOI: 10.14260/jemds/2021/136 formation of newer HAP crystals, which are larger and more resistant to acid dissolution. An insight into the caries process’s multifactorial aetiopathogenesis has How to Cite This Article: resulted in a paradigm shift towards minimally invasive dentistry. This era of Batra A, Shetty V. Non-fluoridated personalised care using the medical model for caries management assimilates the remineralising agents - a review of signs of examining, diagnosing, intercepting, and managing dental caries at a literature. J Evolution Med Dent Sci microscopic level. Fluoride mediated salivary remineralisation system is considered 2021;10(09):638-644, DOI: 10.14260/jemds/2021/136 the cornerstone of non-invasive approach for managing non-cavitated carious lesions. However, the effect of fluoride was found to be limited to the outer surface of Submission 09-10-2020, the tooth, and it was observed that fluoride does not influence the modifiable factors Peer Review 22-12-2020, in dental caries such as the biofilm.
    [Show full text]